Imunodiagnostika - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 115,104 | 256,513 | 409,299 | 737,675 | 828,640 | 521,378 | 871,720 | 885,157 |
| Profit before tax | -157,618 | 200 | 4,018 | 101 | 6,122 | 32,433 | -421,468 | -1,297,154 |
| Net profit | -157,618 | 200 | 4,018 | -2,083 | 6,122 | 31,899 | -421,468 | -1,297,154 |
| Equity | -7,687 | 402,876 | 406,894 | 404,811 | 415,098 | 446,997 | 25,528 | 1,387,783 |
| Liabilities | 931,149 | 1,138,038 | 1,502,530 | 2,509,827 | 2,227,953 | 1,985,372 | 2,475,964 | 778,164 |
| Non-current assets | 977,968 | 1,210,976 | 1,813,891 | 2,030,273 | 1,907,657 | 1,977,071 | 2,116,563 | 1,843,552 |
| Current assets | 241,507 | 622,108 | 443,269 | 948,536 | 732,947 | 451,991 | 381,595 | 840,915 |
| Total assets | 1,219,475 | 1,833,084 | 2,257,160 | 2,978,809 | 2,640,604 | 2,429,062 | 2,498,158 | 2,684,467 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 78,307 | 78,440 | 73,232 |
| Social insurance contributions | - | - | - | - | - | 90,263 | 72,516 | 103,477 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +44.2% | +122.9% | +59.6% | +80.2% | +12.3% | -37.1% | +67.2% | +1.5% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -12.9% | 0.0% | 0.2% | -0.1% | 0.2% | 1.3% | -16.9% | -48.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | 0.0% | 1.0% | -0.5% | 1.5% | 7.1% | -1651.0% | -93.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -136.9% | 0.1% | 1.0% | -0.3% | 0.7% | 6.1% | -48.3% | -146.5% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -136.9% | 0.1% | 1.0% | 0.0% | 0.7% | 6.2% | -48.3% | -146.5% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 2.8 | 3.7 | 6.2 | 5.4 | 4.4 | 97.0 | 0.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 6,872 | 12,167 | 16,264 | 25,292 | 31,567 | 32,757 | 63,016 | 48,063 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Imunodiagnostika - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-08-26 | 2026-08-30 | 7043.75 |
| 2026-08-23 | 2026-08-23 | 7043.75 |
| 2026-08-19 | 2026-08-19 | 7043.75 |
| 2026-07-19 | 2026-07-30 | 7562.12 |
| 2026-07-16 | 2026-07-17 | 7562.12 |
| 2025-08-19 | 2025-08-29 | 7606.89 |
| 2025-07-16 | 2025-07-28 | 6663.62 |
| 2025-06-11 | 2025-06-12 | 4858.86 |
| 2025-06-08 | 2025-06-09 | 4858.86 |
| 2025-05-29 | 2025-06-04 | 4858.86 |
| 2025-05-22 | 2025-05-28 | 5071.56 |
| 2025-05-16 | 2025-05-21 | 5071.56 |
| 2025-03-18 | 2025-03-30 | 3496.46 |
| 2025-02-10 | 2025-02-10 | 3010.69 |
| 2025-01-16 | 2025-02-02 | 3010.69 |
| 2022-03-16 | 2022-03-20 | 58.34 |
| 2022-02-17 | 2022-03-13 | 1207.41 |
| 2022-02-01 | 2022-02-14 | 2356.49 |
| 2022-01-26 | 2022-01-31 | 2521.97 |
| 2022-01-18 | 2022-01-25 | 2156.79 |
| 2022-01-06 | 2022-01-12 | 3972.15 |
| 2021-12-28 | 2022-01-05 | 5972.15 |
| 2021-12-20 | 2021-12-27 | 7121.23 |
| 2021-12-16 | 2021-12-19 | 7121.23 |
| 2021-12-10 | 2021-12-14 | 7300.04 |
| 2021-11-16 | 2021-12-09 | 7450.09 |
| 2021-11-04 | 2021-11-14 | 8591.31 |
| 2021-10-21 | 2021-11-03 | 8718.95 |
| 2021-10-18 | 2021-10-20 | 20099.09 |
| 2021-10-01 | 2021-10-17 | 9900.11 |
| 2021-09-30 | 2021-09-30 | 9892.08 |
| 2021-09-29 | 2021-09-29 | 9900.08 |
| 2021-09-16 | 2021-09-28 | 21332.16 |
Imunodiagnostika - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company Imunodiagnostika is: 0 €
| From | To | Overdue, € |
|---|---|---|
| 2026-08-28 | 2026-09-02 | 0.06 |
| 2026-08-12 | 2026-08-17 | 1479.23 |
| 2025-12-15 | 2025-12-15 | 0.06 |
| 2025-11-18 | 2025-11-18 | 3.06 |
| 2025-11-15 | 2025-11-17 | 3965.61 |
| 2025-11-14 | 2025-11-14 | 3931.92 |
| 2025-09-14 | 2025-09-14 | 1058.6 |
| 2025-09-05 | 2025-09-08 | 72.01 |
| 2025-09-01 | 2025-09-04 | 71.93 |
| 2025-08-29 | 2025-08-31 | 71.58 |
| 2025-08-28 | 2025-08-28 | 1111.58 |
| 2025-08-15 | 2025-08-18 | 4835.75 |
| 2025-08-14 | 2025-08-14 | 4834.5 |
| 2025-04-17 | 2025-04-18 | 17.78 |
| 2025-04-16 | 2025-04-16 | 2603.15 |
| 2025-02-20 | 2025-02-24 | 1.0 |
| 2025-02-14 | 2025-02-17 | 47.59 |
| 2024-12-13 | 2024-12-14 | 3089.23 |
| 2024-12-12 | 2024-12-12 | 3071.63 |
| 2024-10-12 | 2024-10-15 | 1151.13 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Imunodiagnostika, UAB (code 303064228) is a Private Limited Liability Company engaged in research and experimental development on other natural sciences and engineering. In 2025, the company generated revenue of €885.2K, up 1.5% year on year and 69.8% over two years, showing continued expansion in sales volume. At the same time, profitability deteriorated sharply: net loss reached €1.30M in 2025 versus a loss of €421.5K in 2024 and a net profit of €31.9K in 2023. The latest profit margin was -146.5%, reflecting the scale of the loss relative to revenue. Balance sheet size increased to €2.68M, with equity of €1.39M and liabilities of €778.2K at year-end 2025. Equity strengthened materially compared with 2024, while liabilities declined. Key efficiency indicators remained weak, with ROE at -93.5%, ROA at -48.3% and asset turnover at 0.33x. Revenue per employee was €49.2K, while profit per employee was -€72.1K, indicating that higher turnover in 2025 was not matched by financial performance.